Sage Therapeutics (SAGE) Price Target Raised to $225.00 at Chardan Capital

SAGE Therapeutics Inc

Its down 0.13, from 1.11 in 2017Q1. Oppenheimer Asset Management Inc. increased its stake in shares of Sage Therapeutics by 412.9% in the 3rd quarter.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business.

Deutsche Savings Bank Ag reported 660,413 shares. Cwm Limited Co invested 0% of its portfolio in Sage Therapeutics, Inc. (NASDAQ:SAGE). Morgan Stanley reported 50,373 shares. Chardan Capital reiterated a "hold" rating on shares of Sage Therapeutics in a research report on Wednesday, September 13th. Victory Capital Mgmt accumulated 445,485 shares or 0.08% of the stock. Grp Inc invested in 0.01% or 21,441 shares. Nicholas Invest Limited Partnership stated it has 0.43% of its portfolio in Sage Therapeutics, Inc. The results waned from their mid-stage results, but investors backed the notion that Sage has something important in a field marked by repeated setbacks. Denver Llc holds 0.02% or 4,403 shares in its portfolio. (NASDAQ:SAGE). 78,900 were reported by Gam Hldg Ag. Palo Alto Invsts Ltd Liability Corporation holds 3.84% or 1.03 million shares in its portfolio. University Of Notre Dame Du Lac holds 0.82% or 34,936 shares in its portfolio. Bessemer Group Inc. bought a new position in shares of Sage Therapeutics in the 3rd quarter worth about $141,000. Sage is now up by 74.4 percent after reaching a record intraday high. This technical setup was reported by An all time high points to a stock which has the most positive fundamentals ever. Tightening the gaze, stock performance for the last 5 trading days is -2.39%. About 6.61M shares traded or 676.95% up from the average.

Sentiment on the street is mostly bullish on SAGE stock. It has outperformed by 99.75% the S&P500. They expect $-2.00 EPS, down 33.33 % or $0.50 from last year's $-1.5 per share. The biopharmaceutical company reported ($1.97) earnings per share for the quarter, topping the consensus estimate of ($1.98) by $0.01. Therefore 88% are positive.

ILLEGAL ACTIVITY WARNING: "Sage Therapeutics (SAGE) Given New $246.00 Price Target at Leerink Swann" was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. The stock has a mean rating of buy among analysts on FactSet. SAGE Therapeutics had 45 analyst reports since September 3, 2015 according to SRatingsIntel. The rating was maintained by Canaccord Genuity on Tuesday, September 12 with "Buy". Cowen & Co maintained it with "Buy" rating and $90.0 target in Tuesday, September 12 report. The firm earned "Buy" rating on Thursday, August 3 by BMO Capital Markets. Stifel Nicolaus initiated it with "Buy" rating and $90 target in Monday, November 14 report. The stock has "Neutral" rating by H.C. Wainwright on Wednesday, February 22. The firm earned "Buy" rating on Tuesday, September 12 by Canaccord Genuity. Bank of America maintained it with "Buy" rating and $101 target in Thursday, November 16 report.

More recent Sage Therapeutics, Inc. (NASDAQ:SAGE) were released by: and their article: "SAGE Therapeutics Options Traders Don't Buy Depression Drug Breakout" published on December 07, 2017 as well as's news article titled: "Mid-Day Market Update: Duluth Holdings Drops Following Q3 Results; SAGE ..." with publication date: December 07, 2017. More interesting news about Sage Therapeutics, Inc.

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases, as well as sexual dysfunction.



Latest news

LeBron James says Derrick Rose doesn't owe team an apology
According to Adrian Wojnarowski of ESPN, Rose flew to Cleveland on Monday and met with the team's front office personnel and will begin rehab on his ankle injury.

THQ Nordic Reveal Teased for Game Awards
In addition to this, it's safe to expect details on the next expansion to The Legend of Zelda Breath of the Wild . The Game Awards 2017 will air live tonight, December 7, starting with the pre-show at 8:30 PM ET / 5:30 PM PT.

Miami Marlins trade second baseman Dee Gordon to Seattle Mariners
And more on his speed: Since 2014, Gordon leads all players in triples with 35 while ranking second in stolen bases with 212. In the trade, the Mariners also got $1 million in global pool money, undoubtedly to bolster their pursuit of Shohei Ohtani.

$0.37 EPS Expected for Bed Bath & Beyond Inc. (BBBY)
The retailer reported $0.67 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.95 by ($0.28). Moreover, Cambridge Investment Research Advisors Inc. has 0% invested in the company for 21,729 shares. (NASDAQ:BBBY).

Chiefs are four-point favorites at home vs. Raiders
The Chiefs opened as four-point favorites; the total was 47.5 early in the week, according to sportsbooks monitored by OddsShark. At the end of the day, someone has to win the AFC West and sit in that (likely) four-seed in the AFC playoffs.

Other news